Gazala Siddiqui, MD
Urogynecology and Reconstructive Pelvic Surgery · Houston, TXNPI 1346265725
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,906 of the $81,407 with a category attached, or 65.0%. 26 manufacturers reported payments, led by Astellas Pharma US Inc at 43.7% of the total. Reporting peaked in 2023 at $47,780 and has fallen 96.7% since, to $1,560 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $476.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$36K
- Sumitomo Pharma America, Inc.$26K
- Baxter Healthcare$8K
- Urovant Sciences Inc$7K
- Boston Scientific$2K
- Johnson & Johnson$938
- plus $2K from 20 others
What the payments were for
- Consulting fees$12,78816%
- Speaking & faculty fees$52,90665%
- Travel & lodging$7,6259%
- Food & beverage$6,3378%
- Education$1,5562%
- Entertainment$1960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 46 | $35,534 |
| Sumitomo Pharma America, Inc. | 35 | $25,543 |
| Baxter Healthcare | 12 | $8,303 |
| Urovant Sciences Inc | 9 | $6,859 |
| Boston Scientific | 30 | $2,105 |
| Johnson & Johnson | 1 | $938 |
| Caldera Medical, Inc | 4 | $774 |
| Coloplast | 4 | $254 |
| Coopersurgical, Inc. | 4 | $214 |
| Renovia Inc | 2 | $135 |
| Gynesonics, Inc. | 1 | $132 |
| Hologic Sales And Service, LLC | 5 | $104 |
| Astellas Pharma Global Development | 1 | $104 |
| Applied Medical Resources Corporation | 2 | $101 |
| Smith+Nephew | 2 | $55 |
| Medtronic | 1 | $39 |
| Aspira Women's Health Inc | 2 | $32 |
| AbbVie | 2 | $31 |
| Axonics, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Olympus America Inc. | 1 | $20 |
| Avanos Medical | 1 | $19 |
| Exeltis, USA Inc. | 1 | $18 |
| Evofem Biosciences, Inc. | 1 | $18 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Davol Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEMTESA$32,170
- Veozah$23,561
- MYRBETRIQ$11,137
- FLOSEAL$6,499
- TISSEEL$3,887
- SEPRAFILM$1,665
- DERMABOND Portfolio$938
- Desara$694
- Vertessa$694
- Solyx SIS System$473
- GENERAL FEMALE SUI$284
- ALTIS$216
- GENERAL - THERAPIES$150
- SONATA SONOGRAPHY-GUIDED TRANSCERVICAL FIBROID ABLATION SYSTEM$132
- Leva Pelvic Floor Trainer$125
- ADEPT$116
- SOLYX$110
- Uterine Manipulators & Injectors$102
How this compares
$81,407 in reported general payments places this provider in the 90th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
See all urogynecology and reconstructive pelvic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 98 | $92,514 |
| GemtesaVibegron | 49 | $51,149 |
| Mirabegron ErMirabegron | 14 | $11,448 |
| Estradiol | 141 | $7,518 |
| NitrofurantoinNitrofurantoin Macrocrystal | 20 | $263 |
| Tamsulosin Hcl | 22 | $251 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 19 | $187 |
| Cephalexin | 43 | $182 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $35,534 | $92,51498 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $25,543 | $51,14949 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
Other urogynecology and reconstructive pelvic surgery in Houston
- Fiona LindoHouston$66K
- Peter LotzeHouston$48K
- Oluwarotimi NetteyHouston$19K
- Linh DoHouston$11K
- Christine PanHouston$11K
- Apurva PancholyHouston$10K
- Danielle AntoshHouston$8K
- Khadijah EidHouston$8K
- Emily RutledgeHouston$5K
- Sarah RozyckiHouston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.